May 19, 2017 / 6:08 AM / 2 months ago

BRIEF-Hikma sees FY group revenue between $2.0-$2.1 bln at constant currency

1 Min Read

May 19 (Reuters) - Hikma Pharmaceuticals Plc:

* Expect full year group revenue to be in range of $2.0-$2.1 billion in constant currency in 2017

* Updated guidance reflects changes in outlook for Generics business; revised expectation for launch timing of generic version of Advair Diskus

* Maintain full year guidance for our Injectables and branded businesses

* Expect Generics revenue to be around $670 million in 2017

* Expect global Injectables revenue to be between $800-$825 million for FY, core operating margin in high 30s, reflecting step-up in research and development Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below